Patrick Durez
YOU?
Author Swipe
View article: Immune checkpoint-induced arthritis: a comprehensive single-cohort descriptive analysis from clinical evaluation to histology
Immune checkpoint-induced arthritis: a comprehensive single-cohort descriptive analysis from clinical evaluation to histology Open
Background/purpose Immune checkpoint inhibitor-induced arthritis (ICI-IA) is the most common rheumatic immune-related adverse event (irAEs). Its pathogenesis remains unknown. Ultrasound (US)-guided synovial biopsy (USGSB) has been proven t…
View article: Evolution from early to difficult-to-treat rheumatoid arthritis: incidence and risk factors in the ERA uclouvain Brussels cohort
Evolution from early to difficult-to-treat rheumatoid arthritis: incidence and risk factors in the ERA uclouvain Brussels cohort Open
View article: Precision medicine and the chaos theory in rheumatoid arthritis
Precision medicine and the chaos theory in rheumatoid arthritis Open
View article: POS0467 Methotrexate use influenced the effect of inflammation on cardiovascular risk differently in anticitrullinated protein antibody negative and positive patients with rheumatoid arthritis
POS0467 Methotrexate use influenced the effect of inflammation on cardiovascular risk differently in anticitrullinated protein antibody negative and positive patients with rheumatoid arthritis Open
View article: POS0742 THE EFFECT OF DISEASE ACTIVITY ON CARDIOVASCULAR RISK VARIES ACCORDING TO RHEUMATOID FACTOR AND ANTICITRULLINATED PROTEIN ANTIBODY STATUS IN PATIENTS WITH RHEUMATOID ARTHRITIS
POS0742 THE EFFECT OF DISEASE ACTIVITY ON CARDIOVASCULAR RISK VARIES ACCORDING TO RHEUMATOID FACTOR AND ANTICITRULLINATED PROTEIN ANTIBODY STATUS IN PATIENTS WITH RHEUMATOID ARTHRITIS Open
View article: POS0162 THE INFLUENCE OF BODY MASS INDEX ON CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS VARIES ACROSS ANTICITRULLINATED PROTEIN ANTIBODY STATUS AND BIOLOGIC USE
POS0162 THE INFLUENCE OF BODY MASS INDEX ON CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS VARIES ACROSS ANTICITRULLINATED PROTEIN ANTIBODY STATUS AND BIOLOGIC USE Open
View article: POS0753 REAL-WORLD EFFECTIVENESS OF FILGOTINIB PER TREATMENT LINE IN RHEUMATOID ARTHRITIS
POS0753 REAL-WORLD EFFECTIVENESS OF FILGOTINIB PER TREATMENT LINE IN RHEUMATOID ARTHRITIS Open
View article: POS0751 OPTIMAL TREATMENT STRATEGIES FOLLOWING JAKi DISCONTINUATION IN RHEUMATOID ARTHRITIS
POS0751 OPTIMAL TREATMENT STRATEGIES FOLLOWING JAKi DISCONTINUATION IN RHEUMATOID ARTHRITIS Open
View article: POS0874 THE EFFECT OF INFLAMMATION ON CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS VARIES ACCORDING TO SEX AND ANTICITRULLINATED PROTEIN ANTIBODY STATUS
POS0874 THE EFFECT OF INFLAMMATION ON CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS VARIES ACCORDING TO SEX AND ANTICITRULLINATED PROTEIN ANTIBODY STATUS Open
View article: Lung involvement in rheumatoid arthritis, a prospective study
Lung involvement in rheumatoid arthritis, a prospective study Open
Background The prevalence of lung involvement in rheumatoid arthritis (RA) remains elusive. Therefore, we set up a multicentric prospective study to investigate the presence of interstitial lung disease (ILD), emphysema, bronchiolitis and …
View article: Inclusion of fibrinoid necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA Cohort
Inclusion of fibrinoid necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA Cohort Open
View article: Analysis of synovitis patterns in early RA supports the importance of joint-specific factors
Analysis of synovitis patterns in early RA supports the importance of joint-specific factors Open
View article: Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry
Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry Open
View article: Two Broad Categories Overlapping With Rheumatoid Arthritis Observed in Synovial Biopsies from Patients With Juvenile Idiopathic Arthritis
Two Broad Categories Overlapping With Rheumatoid Arthritis Observed in Synovial Biopsies from Patients With Juvenile Idiopathic Arthritis Open
Objective The objective is to characterize transcriptomic profiles and immune cell composition and distribution in juvenile idiopathic arthritis (JIA) synovial biopsies, assess for associations of these features with clinical parameters, a…
View article: Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study Open
Objectives To assess the safety and efficacy of upadacitinib versus adalimumab from SELECT-COMPARE over 5 years. Methods Patients with rheumatoid arthritis and inadequate response to methotrexate were randomised to receive upadacitinib 15 …
View article: Inclusion of Fibrinoid Necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA Cohort
Inclusion of Fibrinoid Necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA Cohort Open
Objective Rheumatoid Arthritis (RA) often exhibits suboptimal treatment response despite early diagnosis and treatment. This study aimed to analyze Early Rheumatoid Arthritis (ERA) synovial biopsies through histology and immunohistochemist…
View article: Sexual dysfunction in male patients treated with methorexate for arthritis: Analysis of the IIEF5 questionnaire and hormonal status
Sexual dysfunction in male patients treated with methorexate for arthritis: Analysis of the IIEF5 questionnaire and hormonal status Open
View article: Trajectory Evolution from Early to Difficult-to-Treat Rheumatoid Arthritis: Incidence and Associated Risk Factors in the Early Rheumatoid Arthritis Uclouvain Brussels Cohort
Trajectory Evolution from Early to Difficult-to-Treat Rheumatoid Arthritis: Incidence and Associated Risk Factors in the Early Rheumatoid Arthritis Uclouvain Brussels Cohort Open
View article: Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials Open
View article: Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis
Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis Open
View article: AB1579 ULTRASOUND JOINT ASSESSMENTS INCREASE DETECTION OF POLYARTICULAR JOINT INVOLVEMENT IN CHECKPOINT INHIBITORS-INDUCED ARTHRITIS
AB1579 ULTRASOUND JOINT ASSESSMENTS INCREASE DETECTION OF POLYARTICULAR JOINT INVOLVEMENT IN CHECKPOINT INHIBITORS-INDUCED ARTHRITIS Open
View article: POS0314 CAN METHOTREXATE INFLUENCE SEXUAL DYSFUNCTION IN MALE PATIENTS: ANALYSIS OF THE IIEF5 QUESTIONNAIRE AND HORMONAL STATUS
POS0314 CAN METHOTREXATE INFLUENCE SEXUAL DYSFUNCTION IN MALE PATIENTS: ANALYSIS OF THE IIEF5 QUESTIONNAIRE AND HORMONAL STATUS Open
View article: AB0425 REAL-WORLD EFFECTIVENESS OF FILGOTINIB IN BELGIAN PATIENTS WITH RHEUMATOID ARTHRITIS
AB0425 REAL-WORLD EFFECTIVENESS OF FILGOTINIB IN BELGIAN PATIENTS WITH RHEUMATOID ARTHRITIS Open
View article: AB0421 REAL-WORLD EFFECTIVENESS OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS
AB0421 REAL-WORLD EFFECTIVENESS OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS Open
View article: POS0448 IDENTIFICATION OF JOINT LOCATIONS IN AN EARLY RHEUMATOID ARTHRITIS COHORT AS A CHARACTERISTIC OF DISEASE SEVERITY AND RESPONSE TO METHOTREXATE, DATA FROM THE ERA-UCLOUVAIN BRUSSELS COHORT
POS0448 IDENTIFICATION OF JOINT LOCATIONS IN AN EARLY RHEUMATOID ARTHRITIS COHORT AS A CHARACTERISTIC OF DISEASE SEVERITY AND RESPONSE TO METHOTREXATE, DATA FROM THE ERA-UCLOUVAIN BRUSSELS COHORT Open
View article: POS1345 PAIN OVER 5 YEARS IN OUR EARLY RHEUMATOID ARTHRITIS UCLOUVAIN BRUSSELS COHORT: RESULTS AND CORRELATION WITH CLINICAL RESPONSE, QUALITY OF LIFE
POS1345 PAIN OVER 5 YEARS IN OUR EARLY RHEUMATOID ARTHRITIS UCLOUVAIN BRUSSELS COHORT: RESULTS AND CORRELATION WITH CLINICAL RESPONSE, QUALITY OF LIFE Open
View article: POS0849 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: 5-YEAR DATA FROM THE SELECT-COMPARE STUDY
POS0849 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: 5-YEAR DATA FROM THE SELECT-COMPARE STUDY Open
View article: AB0454 SAFETY OF FILGOTINIB IN PATIENTS WITH RA: LABORATORY ANALYSIS RESULTS FROM A LONG-TERM EXTENSION STUDY
AB0454 SAFETY OF FILGOTINIB IN PATIENTS WITH RA: LABORATORY ANALYSIS RESULTS FROM A LONG-TERM EXTENSION STUDY Open
BACKGROUND: Filgotinib (FIL) is a Janus kinase (JAK) 1 preferential inhibitor, approved for treatment of moderate to severe active RA in Europe, the UK, and Japan. Graded laboratory abnormalities from placebo-controlled analyses and long-t…
View article: OP0129 EFFECTIVENESS OF COBRA-SLIM WITH OR WITHOUT EARLY ACCESS TO A TEMPORARY 6-MONTH COURSE OF ETANERCEPT IN EARLY RA: PRIMARY OUTCOME OF THE 2-YEAR, PRAGMATIC, RANDOMISED CARERA2020 TRIAL
OP0129 EFFECTIVENESS OF COBRA-SLIM WITH OR WITHOUT EARLY ACCESS TO A TEMPORARY 6-MONTH COURSE OF ETANERCEPT IN EARLY RA: PRIMARY OUTCOME OF THE 2-YEAR, PRAGMATIC, RANDOMISED CARERA2020 TRIAL Open
BACKGROUND: EULAR recommends methotrexate (MTX), combined with shortterm glucocorticoids as first-line treatment for early Rheumatoid Arthritis (RA). In the CareRA trial, the COBRA-Slim regimen (MTX 15 mg/w + step-down prednisone 30, 20, 1…
View article: AB0226 PREDICTORS OF response AFTER CESSATION OF JAKI THERAPY IN PATIENTS WITH RA
AB0226 PREDICTORS OF response AFTER CESSATION OF JAKI THERAPY IN PATIENTS WITH RA Open
BACKGROUND: In a previous study based on data from the Belgian register “Tool for Administrative Reimbursement Drug Information Sharing” (TARDIS)[1], IL6 inhibitors showed a better clinical response after JAKi cessation compared to other b…